Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.

Authors:

Thiery-Vuillemin A, De Bono J, Saad F, et al.

Year

2020

Conference

ASCO Annual Meeting

Location

Virtual

Start Date

May 29

End Date

Jun 2